and follicular T helper cell and suppressed T H 17 cell responses. The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics. Treatment with the Janus kinase 1/2 inhibitor ruxolitinib reduced hyperresponsiveness to type I and II interferons, normalized T H 1 and follicular T helper cell responses, improved T H 17 differentiation, cured mucocutaneous candidiasis, and maintained remission of immune-mediated cytopenias. Conclusions: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses. Janus kinase inhibitor therapy could represent an effective targeted treatment for long-term disease control in severely affected patients for whom hematopoietic stem cell transplantation is not available. Signal transducer and activator of transcription 1 (STAT1) is a member of the STAT family of transcription factors which play a key role in the cellular response to interferons and is a central component in many other signaling pathways, including interleukins, growth factors, and hormones. In response to extracellular receptor stimulation, Janus kinase (JAK) activation leads to phosphorylation of cytoplasmic STAT1, followed by homodimerization or heterodimerization with other phosphorylated STAT family members. The dimers translocate into the nucleus and bind designated promoter elements to activate transcription of their respective target genes. [1] [2] [3] STAT1 is the target of both loss-of-function and gain-offunction (GOF) mutations. Whereas the former are associated with susceptibility to mycobacterial and/or viral infections, the latter give rise to a mixed phenotype of autoimmunity, mucocutaneous candidiasis, and invasive fungal infections related to augmented T H 1 and diminished T H 17 cell responses. [4] [5] [6] [7] [8] [9] STAT1 GOF mutations prompt a signal-induced increase in levels of phosphorylated STAT1 (phospho-STAT) and amplified transcription of interferon-responsive genes, which lead to autoimmunity. 5, 6, 10 Delayed dephosphorylation with ensuing accumulation of phospho-STAT1 in the nucleus has been proposed as a mechanistic basis in most reported cases. 1, 6, [11] [12] [13] [14] [15] How increased STAT1 activity compromises T H 17 immunity to result in chronic mucocutaneous candidiasis and other invasive fungal and viral infections is less well understood. 12, 16, 17 Excessive production of interferons, IL-27, and programmed death (PD) 1 ligand can directly impair T H 17 cell differentiation. 18, 19 Alternatively, predominance of STAT1 signaling over STAT3 signaling might deviate the response to IL-6, IL-21, and IL-23 away from STAT3, which normally mediates T H 17 cell development. 1, 18 The clinical management of patients with STAT1 GOF mutations remains challenging. [20] [21] [22] In particular, controlling autoimmunity is difficult because conventional immunosuppression adds to the already increased risk of infections. Therapy-refractory or lifethreatening disease is considered a noncanonical indication for allogeneic hematopoietic stem cell transplantation; however, the immune phenotype of STAT1 GOF mutations amplifies the transplant-related risk for uncontrolled infections and graftversus-host disease, contributing further to the poor prognosis. 21 , 23 Liu et al 24 were the first to provide proof of principle that JAK inhibitors can successfully treat STAT1-mediated hyperresponsiveness to interferons in patients with vascular and pulmonary syndrome caused by mutations in TMEM173, which encodes the stimulator of interferon genes. Higgins et al 10 reported hair regrowth in a patient with alopecia areata secondary to a STAT1 GOF mutation after treatment with ruxolitinib. Most recently, M€ ossner et al 25 observed improvement of chronic mucocutaneous candidiasis with ruxolitinib and a reactive increase in IL-17A/F levels.
Here we describe the immunophenotypic analysis of a patient with life-threatening autoimmune cytopenias and a novel GOF mutation in the linker domain of STAT1. Importantly, in addition to increasing T H 1 and suppressing T H 17 cell differentiation, the augmented STAT1 activity dysregulated follicular T helper (T FH ) cell responses. This finding was corroborated in a different patient with known STAT1 T385M GOF mutation in the DNA-binding domain who presented solely with chronic mucocutaneous candidiasis and opportunistic infections but without clinical evidence of autoimmunity. 13, 26, 27 Long-term treatment with the JAK inhibitor ruxolitinib decreased the increased STAT1 phosphorylation, reversed the dysregulated T H 1 and T FH cell development, improved the previously impaired T H 17 response, and enabled effective control of the autoimmune cytopenias. This is the first report demonstrating mechanistic evidence that pharmacologic manipulation of the JAK-STAT pathway in patients with STAT1 GOF mutations leads to reversal of the immune dysregulation phenotype and provides proof of principle that JAK inhibitors are not only effective in treating active autoimmune disease and immunodeficiency secondary to hyperresponsiveness of STAT1 but also in reversing the aberrant priming of naive cells, thereby maintaining long-term disease control and sustained remission.
METHODS

Patients and healthy subjects
All study participants were recruited after obtaining written informed consent approved by the Boston Children's Hospital Institutional Review Board.
Pharmacotherapy
The IL-1 receptor antagonist anakinra (Kineret; Sobi, Stockholm, Sweden) was administered intravenously twice daily at a dose of 100 mg.
Four infusions with equine anti-thymocyte globulin (ATG; Atgam; Pfizer, New York, NY) were administered intravenously at a dose of 40 mg/kg body 
STAT1 sequencing
Exons 3 to 23 of STAT1, including exon/intron boundaries, were amplified from genomic DNA by means of PCR and sequenced bidirectionally with dye-terminator chemistry. PCR amplification of exon 20 was carried out with the following primers: STAT1E20_F (GATAAGAGCGGGGAGGG) and STAT1E20_R (TGAAGCTGGACTCAGGC). The mutation was predicted to be deleterious by using SIFT and PolyPhen-2.
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Protein modeling
The STAT1 E545K mutant structure was generated by using SWISS-MODEL with STAT1 structures (PDB code: 1YVL and 1BF5). [30] [31] [32] [33] Structural alignment was performed in Coot, and molecular representation was displayed in PyMOL. 34 
Antibodies and flow cytometry
Monoclonal antibodies to the following human proteins were used for staining: CD3 (UCHT1), CD4 (RPA-T4), CD8 (RPA-T8), CD45RA (HI100), CCR7 (G043H7), inducible costimulator (ICOS; C398.4A), PD1 (eBioJ105), CXCR5 (MU5UBEE), phospho-STAT1 (KIKSI0803), and phospho-STAT3 (LUVNKLA; all from eBioscience, San Diego, Calif); IL-17 (BL168), IFN-g (4S.B3), CCR6 (G034E3), and CXCR3 (G025H7; all from BioLegend, San Diego, Calif); and STAT1 (246523; R&D Systems, Minneapolis, Minn). Appropriate isotype controls were used in parallel. PBMCs were incubated with mAbs against surface proteins for 30 minutes on ice.
Intracellular STAT1 staining
STAT1 staining was performed with an eBioscience Fixation/Permeabilization kit, according to the manufacturer's instructions.
Phospho-STAT1 and phospho-STAT3 staining
PBMCs were stimulated in complete medium for 20 minutes with appropriate cytokines: human IFN-b (20 ng/mL; Miltenyi Biotec, Bergisch Gladbach, Germany), IFN-g, or IL-21 (20 ng/mL; PeproTech, Rocky Hills, NJ). Subsequently, PBMCs were fixed with 2% paraformaldehyde for 20 minutes on ice, permeabilized with 90% methanol for 30 minutes on ice, and stained with CD3, CD4, phospho-STAT1, and phospho-STAT3 mAbs in PBS for 30 minutes.
Ex vivo cytokine detection
PBMCs were isolated from whole blood by means of centrifugation over a Ficoll gradient and stimulated in complete medium in the presence of anti-CD2/CD3/CD28 beads (Miltenyi Biotec) and 100 U/mL recombinant human IL-2 (PeproTech) for 2 days. Subsequently, cell suspensions were incubated with phorbol 12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich, St Louis, Mo), ionomycin (500 ng/mL; Sigma-Aldrich), and GolgiPlug (BD Biosciences, San Jose, Calif), according to the manufacturer's instructions, in complete medium for 4 hours before surface staining. Permeabilization and intracellular IFN-g and IL-17 staining were carried out with an eBioscience Fixation/Permeabilization kit, as described above. Data were collected with an LSRFortessa cytometer (BD Biosciences) and analyzed with FlowJo software (TreeStar, Ashland, Ore).
JAK inhibitor treatment in vitro
PBMCs were incubated for 4 hours in the presence of different concentrations of ruxolitinib, which is primarily a JAK1/2 inhibitor (10 or 100 nmol/L; Selleckchem, Houston, Tex), and tofacitinib, which is predominantly a JAK3 inhibitor (10 and 100 nmol/L; Sigma-Aldrich), or vehicle (dimethyl sulfoxide) alone before stimulation with recombinant human IFN-b (20 ng/mL; Miltenyi Biotec), IFN-g, or IL-21 (20 ng/mL, PeproTech). 
T helper cell subset differentiation
Statistical analysis
Comparisons between the patient and healthy control subjects were analyzed by using the unpaired Student t test and 1-or 2-way ANOVA with posttest analysis. Two-sided P values of less than .05 were considered statistically significant.
RESULTS
Refractory autoimmune cytopenias associated with a novel STAT1 GOF mutation
A 10-year-old girl with a longstanding history of Evans syndrome manifesting in autoimmune hemolytic anemia and immune thrombocytopenia presented to our institution with an acute exacerbation of her disease (in the following referred to as ''the'' patient or patient 1). She required daily packed red blood cell transfusions to keep her hemoglobin level at greater than 6 g/dL and experienced systemic bleeding symptoms refractory to platelet transfusion. At presentation, the patient had already been treated with a prolonged course of steroids and multiple doses of intravenous immunoglobulins. Although these therapies did not induce remission, withdrawal of steroids spurred the rate of hemolysis further, necessitating continued glucocorticoid therapy.
The patient had a history of chronic mucocutaneous candidiasis involving her nails, oral mucosa, and vaginal tract. She also had chronic diarrhea and severe chronic lung disease with respiratory insufficiency requiring supplemental oxygen. She was a poor responder to vaccines and had been treated with immunoglobulin replacement over extended periods of her life. The parents were nonconsanguineous, and there was no family history of autoimmunity, immunodeficiency, or other blood dyscrasias. HLA typing revealed that the patient's only sibling was not a match.
A comprehensive diagnostic evaluation revealed positive antiplatelet IgM antibody levels, as well as a complement-fixing, high-affinity, high-thermal-amplitude cold agglutinin. Consequently, the patient received a course of the anti-CD20 mAb rituximab followed by the anti-complement C5 antibody eculizumab without clinical improvement. Over the course of the following 6 weeks, the patient's reticulocyte count and absolute neutrophil count started to decrease, whereas ferritin and lactate dehydrogenase levels were increasing. Serial bone marrow biopsies demonstrated a steady decrease in bone marrow cellularity from greater than 70% before admission to less than 10% 11 weeks later, leading to the diagnosis of acquired aplastic anemia. A bone marrow aspirate also revealed occasional CD163 1 hemophagocytic histiocytes, for which treatment with the IL-1 receptor antagonist anakinra for presumed macrophage activation syndrome was added to the baseline steroid therapy. A diagnostic workup for genetic causes of bone marrow failure was nonrevealing. Accordingly, the patient received standard immunosuppressive therapy for idiopathic aplastic anemia without an available matched sibling donor consisting of 4 doses of equine ATG and cyclosporine. Although the initial posttreatment course was complicated by intraventricular hemorrhage and acute respiratory decompensation, over the following 8-week period, the patient's clinical course stabilized. The absolute neutrophil and reticulocyte counts began to increase, which is consistent with bone marrow recovery in response to treatment with ATG and cyclosporine. However, hemolysis started to flare, and hemoglobin levels rapidly decreased again as soon as steroids were weaned, indicating that ATG and cyclosporine successfully treated the patient's aplastic anemia but did not bring the autoimmune cytopenias into complete remission (Fig 1 and see  Fig E1 in this article's Online Repository at www.jacionline. org). Together with the development of acute steroid-induced diabetes, the need for an alternate therapy to control the persisting autoimmune cytopenias became critical.
Unbiased genetic testing for 200 known/selected inborn errors of immunity identified a monoallelic de novo missense mutation in the coding region of STAT1 that resulted in an amino acid substitution in the linker domain of the protein and was predicted to be deleterious by using SIFT and PolyPhen-2 (c.1633G>A; p.E545K; Fig 2, A and B) . Structure modeling revealed that the E545 residue is far away from the previously proposed STAT1 dimerization interface but close to the SH2 domain, which binds the activating IFN-g receptor peptide, suggesting that this mutation might affect STAT dimer binding to cytokine receptors or kinases. 32 This mutation did not affect expression of total STAT1 protein in CD4
1 and CD8 1 T cells or in B cells at baseline (Fig 2, C, and data not shown) . However, on stimulation of PBMCs with IFN-b (20 ng/mL) or IFN-g (20 ng/mL) the patient's CD4
1 T cells demonstrated a significant increase in STAT1 phosphorylation compared with that seen in control cells (Fig 2, D) . Unlike other reported STAT1 GOF mutations, the E545K mutation did not affect the dephosphorylation kinetics on cytokine deprivation, which led to normalization of phospho-STAT1 expression down to baseline levels in cells from the patient and control subjects over the same amount of time (Fig  2, E) . Similar results were found on stimulation and withdrawal of the patient's CD8 1 T cells with the respective interferon (data not shown). These results suggest that the E545K mutation is an atypical STAT1 GOF mutation leading to hyperphosphorylation of STAT1 in response to type I and II interferons without interfering with the dephosphorylation process.
STAT1
E545K mediates exaggerated T H 1/cytotoxic T type 1 (T C 1) skewing and suppresses T H 17 cell differentiation Examination of PBMCs 6 months after ATG and rituximab therapy revealed that the patient had a higher proportion of IFN-g-producing and lower proportion of IL-17-producing circulating CD4
1 and CD8 1 T cells compared with healthy control subjects (Fig 3, A and B) . To gain insight into the link between the STAT1 E545K mutation and the patient's clinical presentation with autoimmunity, we evaluated the number of T FH cells, which were defined as CD4 
PD1
1 cells.
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The patient's CD4 1 T cells showed an approximately 7-fold increase in the fraction of CXCR5 
PD1
1 T FH cells compared with healthy control cells (Fig 3, C) , which is suggestive of an increased risk of dysregulated humoral immunity conferred by the STAT1 E545K mutation. To corroborate the hypothesis that dysregulated T FH cell immunity is a primary feature of amplified STAT1 activity, we selected a second patient (patient 2) with a different STAT1 ) compared with healthy control subjects. D, CXCR3 and CCR6 expression in CD4 1 CXCR5 1 PD1 1 T cells from patients 1 and 2 and healthy control subjects (gates shown above). *P < .05 and ***P < .001.
mutation, which is known to confer GOF activity based on previous reports in the literature. 13, 26, 27 As expected, CD4 1 T cells from patient 2 displayed exaggerated STAT1-phosphorylation in response to in vitro stimulation with type I and II interferons, which could also be mitigated by in vitro treatment with ruxolitinib (see Fig E2 in this article's Online Repository at www.jacionline.org). Importantly, patient 2 had chronic mucocutaneous candidiasis and opportunistic infectious without any clinical evidence of autoimmunity and had an increase in the fraction of circulating CXCR5 1 PD1 1 T FH cells (Fig 3, C) . The T FH cells of both patient 1 and patient 2 exhibited high expression of the pro-T H 1 chemokine receptor CXCR3 and decreased expression of the pro-T H 17 chemokine receptor CCR6, which is in agreement with previous studies (Fig 3, D) .
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The JAK1/2 inhibitor ruxolitinib suppresses dysregulated STAT1 E545K phosphorylation induced by interferons
The JAK inhibitors ruxolitinib and tofacitinib, which primarily target JAK1/2 and JAK3, respectively, have been used to target dysregulated JAK/STAT activity in patients with different clinical conditions. 10, 24 To investigate which of these 2 JAK inhibitors is most specific in normalizing STAT1 E545K activity without interfering with STAT3 signaling relevant to T H 17 differentiation, we tested the effects of ruxolitinib and tofacitinib on STAT1 and STAT3 activation in response to IFN-b and IFN-g or IL-21 stimulation, respectively. Both drugs suppressed STAT1 and STAT3 phosphorylation in CD4 1 T cells from patient 1 and control subjects in a concentration-dependent manner. Ruxolitinib was more selective in suppressing STAT1 phosphorylation in J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 response to IFN-b stimulation compared with tofacitinib, which is reflective of a lesser half-maximal inhibitory concentration (IC 50 ) necessary to block JAK1/2 activation (Fig 4, A) . 39 In contrast, ruxolitinib was more sparing toward STAT3 phosphorylation in response to IL-21 stimulation, which is reflective of its higher IC 50 toward JAK3 compared with tofacitinib (Fig 4, B) . Optimal effects were achieved with ruxolitinib at a concentration of 10 nmol/L, which decreased the STAT1 phosphorylation in the patient's CD4 1 T cells from more than 400% before treatment to approximately 150% of the STAT1 activity in vehicle-treated control CD4
1 T cells (Fig 4, C) while maintaining more than 80% of baseline STAT3 activity (Fig 4, D) . The suppressive effect of tofacitinib on STAT1 and STAT3 phosphorylation in CD4 1 T cells from control subjects and the patient in response to IFN-b and IL-21 stimulation was dose dependent but nonselective with equal IC 50 values for STAT1 and STAT3, making it less suitable to treat isolated STAT1 hyperreactivity (Fig 4) .
JAK inhibitor treatment controls STAT1 phosphorylation
Based on these in vitro data, we started treating the STAT1 E545K patient (patient 1) with ruxolitinib. We adjusted the ruxolitinib treatment dose in the patient so that STAT1 phosphorylation in response to stimulation with IFN-b and IFN-g in the patient's CD4 1 T cells decreased to approximately 100% relative to that in control CD4
1 T cells (Fig 5, A and B) . At this dose, which is equivalent to 10 mg/m 2 BSA per day, the patient's STAT3 phosphorylation in CD4 1 T cells in response to IL-21 stimulation was maintained at greater than 80% relative to that in control CD4
1 T cells, matching our in vitro findings (Fig 5, C and D) .
Ruxolitinib treatment normalizes amplified T H 1 and improves impaired T H 17 responses
After 3 to 4 months of ruxolitinb therapy at the target dose, the IFN-g production in circulating CD4
1 T cells from the patient decreased significantly, whereas IL-17 production in circulating CD4
1 T cells initially remained low despite clinical improvement in mucocutaneous candidiasis and diarrhea. After more than 1 year of therapy with ruxolitinib and after discontinuation of all other immunosuppressive medications, IFN-g production in CD4
1 T cells from the STAT1 E545K patient remained suppressed to the level seen in normal control cells, whereas IL-17 production increased along with consolidation of the clinical picture (Fig 6, A  and B) . To assess whether ruxolitinib also has an effect on the aberrant priming of undifferentiated cells, we investigated the capacity of naive CD4 1 T cells from patient 1 to polarize into IFN-g-or IL-17-producing T H 1 or T H 17 cells, respectively, by means of in vitro differentiation under T H 0 (anti-CD2/CD3/28), T H 1 (anti-CD2/CD3/28 and IL-12), and T H 17 (anti-CD2/CD3/ 28, IL-6, IL-23, and TGF-b1) conditions (Fig 6, C and D) . Our results revealed that the patient's naive CD4 1 T cells were biased to adopt a T H 1 fate with marked skewing toward IFN-g production under all 3 conditions compared with control T cells. In contrast, IL-17 production was suppressed, especially under T H 17-polarizing conditions. Importantly, the priming of the STAT1 E545K mutation toward a T H 1/T C 1 phenotype and antagonizing T H 17 differentiation was almost entirely reversible with long-term treatment (>12 months) of the patient with ruxolitinib. No further drug was added to the in vitro culture conditions.
Ruxolitinib maintenance therapy reverses dysregulated T FH cell expansion associated with the STAT1 E545K mutation
To investigate whether ruxolitinib is also effective in controlling the augmented T FH response and possible T FH priming caused by STAT1
E545K
, we assessed the in vitro differentiation capacity of naive CD4
1 T cells from patient 1 into T FH cells with TGF-b1, IL-12, and IL-23 before treatment with ruxolitinib and at multiple time points after (3 months, 12 months, and thereafter). 40 After only 3 months of ruxolitinib at the target dose, numbers of circulating T FH cells in the STAT1 E545K patient normalized down to control levels (Fig 7, A and B) and remained stable over 12 months thereafter (data not shown).
To generate evidence that the enlarged T FH compartment is a primary phenotype of the STAT1 E545K mutation and not a One representative experiment of 2 is shown. **P < .01 and ***P < .001, unpaired 2-tailed Student t test (Fig 6, B) or 2-way ANOVA (Fig 6, D) with posttest analysis.
consequence of the longstanding history of autoimmune disease in our patient, we performed in vitro polarization studies showing that naive CD4 1 T cells from patient 1 had a profoundly exaggerated response to stimulation with TGF-b1, IL-12, and IL-23 compared with control cells, which led to the development of an expanded population of CXCR5
1 ICOS 1 T FH -like cells with higher ICOS expression levels. Ruxolitinib inhibited in vitro T FH cell development in response to TGF-b1, IL-12, and IL-23, leading to a number of CXCR5
1 ICOS 1 T FH -like cells in the patient with the STAT1 E545K mutation that was comparable with that in control subjects before treatment (Fig 7, C-E) .
DISCUSSION
In this report we describe that a patient with a novel STAT1 E545K GOF mutation in the linker domain, which is associated with increased STAT1 phosphorylation, immune dysregulation, and intractable life-threatening autoimmune cytopenias, favorably responded to therapy with ruxolitinib. Longterm therapy addressed all immunophenotypic features of the disease, including cytokine-induced STAT1 hyperphosphorylation, amplified T H 1 and T FH cell differentiation, impaired T H 17 immunity, and the respective aberrant priming of naive cells. Ruxolitinib controlled the autoimmune cytopenias, cured mucocutaneous candidiasis and diarrhea, led to a gradual amelioration of pulmonary function (forced vital capacity was 90% and FEV 1 was 80% after ruxolitinib treatmeant, compared with a forced vital capacity of 75% and FEV 1 of 66% prior to initiation of therapy), and allowed us to wean the patient off all other immunosuppressive therapy. Initial concerns that ruxolitinib could cause JAK2-mediated dose-limiting myelosuppression and anemia proved unsubstantiated. Thus JAK inhibitor therapy represents a rational E545K patient before and after treatment compared with control subjects. C, CXCR5 and ICOS expression in in vitro-differentiated T FH -like cells from the patient and control subjects stimulated with TGF-b1, IL-12, and IL-23 in the presence or absence of ruxolitinib. D, Histograms represent frequencies of in vitro-differentiated T FH cells with and without ruxolitinib in the patient and control subjects. E, ICOS mean fluorescence intensity (MFI) in in vitro-differentiated T FH cells with and without ruxolitinib in the patient and control subjects. **P < .01 and ***P < .001, 1-way (Fig 7, B, D , and E) and 2-way (Fig 7, D and E) ANOVA with posttest analysis.
and effective therapy in patients with this disease. As with all immunomodulatory and immunosuppressive medications, careful clinical surveillance for side effects, including serious infections and malignancy, is warranted.
Like other STAT1 GOF mutations, the STAT1 E545K mutation augmented STAT1 phosphorylation in response to cytokine signaling. However, unlike other common STAT1 GOF mutations, it potentiated STAT1 phosphorylation without affecting dephosphorylation after withdrawal of the activating cytokine.
14 Also, it did not perturb the basal levels of phospho-STAT1 absent cytokine stimulation, suggesting that it promoted increased recruitment of STAT1 at the respective cytokine receptor. Of note, STAT3 phosphorylation was normal.
The STAT1 E545K mutation augmented the in vitro polarization of naive CD4 1 T cells into T H 1 and T FH cell subsets while rendering them resistant to T H 17 polarization. Similar skewing of helper T cell subsets was also observed in vivo, with the patient showing increased T H 1 and T FH but decreased T H 17 cell counts in the circulation. Suppressed T H 17 differentiation was noted despite normal STAT3 phosphorylation. Our findings are consistent with those of recent studies demonstrating that STAT1 GOF mutations act distally to suppress STAT3 activation of components of the T H 17 transcriptional program, including RORC, without affecting cytokine-mediated STAT3 phosphorylation.
41 Surprisingly, the STAT1 E545K mutation was associated with a markedly expanded pool of circulating T FH cells. Similar observations were made in a patient (patient 2) with a different STAT1 GOF mutation affecting the DNA-binding domain who was clinically free from any signs of autoimmunity. These findings suggest that a dysregulated T FH cell response is a primary feature of increased STAT1 activity independent of and not secondary to clinical autoimmunity. The molecular mechanisms leading to this enlarged T FH cell compartment are not clear. T FH cell expansion has been associated with humoral autoimmunity, and several monogenic immune dysregulatory diseases with humoral autoimmunity are associated with an expanded T FH cell pool, including cytotoxic T lymphocyte-associated antigen 4 and LPS-responsive beige-like anchor protein deficiency. 36, 42 By decreasing STAT1 hyperphosphorylation, JAK inhibitors combat the sequelae of unopposed interferon release, normalize T H 1 and T FH cell responses, and treat autoimmunity. In our studies long-term JAK inhibitor treatment also promoted T H 17 differentiation of naive CD4 1 T cells in vitro and rescued IL-17 production in vivo, which was clinically reflected by a significant improvement in mucosal immunity under ruxolitinib therapy. This is in line with the observations of Higgins et al 10 and M€ ossner et al 25 who reported improvement of oral candidiasis in response to ruxolitinib and relapse as the drug was withdrawn. Our concerns that JAK inhibition could compromise mucosal immunity further by decreasing STAT3 activity proved unsubstantiated because ruxolitinib only had a minor effect on STAT3 signaling. The observation that ruxolitinib therapy reversed the exaggerated T FH phenotype and priming caused by STAT1 E545K in its entirety is concordant with its ability to control autoimmune manifestations in our patient over a period of more than 18 months. These observations suggest a role for JAK inhibitors as a maintenance treatment to prevent the development of further autoimmune disease, for which patients with STAT1 GOF mutations are at extremely high risk over their lifetime. The availability of a targeted small-molecule therapy is particularly relevant in severely affected patients for whom a donor for allogeneic hematopoietic stem cell transplantation is not available. Even with a suitable donor, the extent of autosensitization and allosensitization in patients with a longstanding history of autoimmunity together with their inherent underlying comorbidities often call the indication to proceed with an allogeneic hematopoietic stem cell transplantation into question.
The findings described above have implications for a broad patient population. Because STAT1 GOF mutations can present with a wide range of clinical phenotypes, heightened clinical vigilance should prompt the physician to consider this diagnosis in any patient with autoimmune disease associated with mucocutaneous candidiasis or other opportunistic infections. Finally, this case illustrates how profoundly knowledge about the molecular underpinnings of autoimmune conditions can affect therapy and outcome.
Note in proof: After online publication, the authors discovered that Fig 7 had an incorrect panel C. This has been amended in the final print version. 
